Should Medtronic’s (MDT) Cardiac and Pain Device Expansion Shape Investors’ View of Its Procedure Strategy?

NodeGuardian

2026-03-27 20:59:21

Abstract generation in progress

Medtronic (MDT) recently received FDA approval for its OmniaSecure defibrillation lead and entered a distribution agreement for the ViaVerte basivertebral nerve ablation system. These moves expand its cardiac and pain management portfolios, reinforcing its position in procedure-based care. While these developments are additive, Medtronic’s overall growth and margin protection in underperforming units remain key factors for its investment narrative, with analysts forecasting a 27% upside to its current price by 2029.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.